DONEVA SNOW: Open Payments
NPI 1649979147 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$619 in 21 payments from 11 companies in 2025. Trend: 2023 $1,245 · 2024 $830 · 2025 $619
Food & beverage: $619
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $170 |
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| E.R. Squibb & Sons, L.L.C. | 1 | $79 |
| Alkermes, Inc. | 3 | $73 |
| Janssen Scientific Affairs, LLC | 1 | $37 |
| Neurocrine BioSciences, Inc. | 1 | $30 |
| Corium, LLC | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $18 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
Products named: CAPLYTA, COBENFY, ARISTADA, INVEGA SUSTENNA, INGREZZA, Azstarys, Qelbree, Dyanavel XR.
Industry payments across MO — which companies pay providers there.
